These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 30687892

  • 1. Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.
    Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K.
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1325-1333. PubMed ID: 30687892
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System.
    Jung SH, Kwon SY, Min JJ, Bom HS, Ahn SY, Jung SY, Lee SS, Park MR, Yang DH, Ahn JS, Kim HJ, Lee JJ.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):107-115. PubMed ID: 30187105
    [Abstract] [Full Text] [Related]

  • 3. Medullary Abnormalities in Appendicular Skeletons Detected With 18F-FDG PET/CT Predict an Unfavorable Prognosis in Newly Diagnosed Multiple Myeloma Patients With High-Risk Factors.
    Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, O'uchi T, Matsue K.
    AJR Am J Roentgenol; 2019 Oct; 213(4):918-924. PubMed ID: 31216203
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of semi-quantitative parameters of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients.
    Wan B, Zhang S, Wang P, Deng P, Dai W.
    Ann Nucl Med; 2023 Mar; 37(3):155-165. PubMed ID: 36528697
    [Abstract] [Full Text] [Related]

  • 5. [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.
    Chen Z, Yang A, Chen A, Dong J, Lin J, Huang C, Zhang J, Liu H, Zeng Z, Miao W.
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1926-1936. PubMed ID: 38286937
    [Abstract] [Full Text] [Related]

  • 6. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.
    Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K.
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1345-1350. PubMed ID: 30903198
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation.
    Stolzenburg A, Lückerath K, Samnick S, Speer M, Kneer K, Schmid JS, Grigoleit GU, Hofmann S, Beer AJ, Bunjes D, Knop S, Buck AK, Einsele H, Lapa C.
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
    [Abstract] [Full Text] [Related]

  • 8. Prognostic Value of Baseline 18F-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study.
    Moon SH, Choi WH, Yoo IR, Lee SJ, Paeng JC, Jeong SY, Lee SW, Kim K, Choi JY.
    Korean J Radiol; 2018 Sep; 19(3):481-488. PubMed ID: 29713226
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis.
    Han S, Woo S, Kim YI, Yoon DH, Ryu JS.
    Eur Radiol; 2021 Jan; 31(1):152-162. PubMed ID: 32809165
    [Abstract] [Full Text] [Related]

  • 10. 11C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET/CT and Prognostic Value.
    Morales-Lozano MI, Rodriguez-Otero P, Sancho L, Nuñez-Cordoba JM, Prieto E, Marcos-Jubilar M, Rosales JJ, Alfonso A, Guillen EF, San-Miguel J, Garcia-Velloso MJ.
    Int J Mol Sci; 2022 Aug 31; 23(17):. PubMed ID: 36077292
    [Abstract] [Full Text] [Related]

  • 11. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
    Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S.
    Clin Nucl Med; 2015 Apr 31; 40(4):303-8. PubMed ID: 25608167
    [Abstract] [Full Text] [Related]

  • 12. Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment.
    Ahn SY, Park HK, Moon JH, Baek DW, Cho HJ, Sohn SK, Kang SR, Min JJ, Bom HS, Hong CM, Jeong SY, Song GY, Yang DH, Ahn JS, Kim HJ, Jung SH, Lee JJ.
    Int J Hematol; 2021 May 31; 113(5):668-674. PubMed ID: 33475961
    [Abstract] [Full Text] [Related]

  • 13. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.
    McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE.
    Clin Cancer Res; 2017 Apr 15; 23(8):1981-1987. PubMed ID: 27698001
    [Abstract] [Full Text] [Related]

  • 14. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.
    Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F.
    J Clin Oncol; 2017 Sep 01; 35(25):2911-2918. PubMed ID: 28686535
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic value of (18)F-FDG PET/CT in newly diagnosed multiple myeloma patients].
    Wang CY, Wu L, Sun CT, Wang X, Xia B, Zhang YZ.
    Zhonghua Yi Xue Za Zhi; 2019 Jan 22; 99(4):301-306. PubMed ID: 30669718
    [Abstract] [Full Text] [Related]

  • 16. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline.
    Cho HJ, Baek DW, Kim JH, Lee J, Chung YK, Jung SH, Song GY, Ahn SY, Ahn JS, Yang DH, Lee JJ, Kim HJ, Hong CM, Jeong SY, Min JJ, Sohn SK, Moon JH.
    Clin Lymphoma Myeloma Leuk; 2022 Feb 22; 22(2):113-120. PubMed ID: 34598908
    [Abstract] [Full Text] [Related]

  • 17. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.
    Paschali A, Panagiotidis E, Triantafyllou T, Palaska V, Tsirou K, Verrou E, Υiannaki E, Markala D, Papanikolaou A, Pouli A, Konstantinidou P, Chatzipavlidou V, Terpos E, Katodritou E.
    Eur J Nucl Med Mol Imaging; 2021 May 22; 48(5):1487-1497. PubMed ID: 33099659
    [Abstract] [Full Text] [Related]

  • 18. The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.
    Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, Zhang W.
    Contrast Media Mol Imaging; 2018 May 22; 2018():4198673. PubMed ID: 30154686
    [Abstract] [Full Text] [Related]

  • 19. A prognostication system based on clinical parameters and [18F]-FDG PET/CT in patients with newly diagnosed multiple myeloma.
    Li J, Zhang X, Qin C, Sun X, Xu X, Cao G, Gai Y, Sun C, Hu Y, Lan X.
    Eur J Nucl Med Mol Imaging; 2023 May 22; 50(6):1665-1670. PubMed ID: 36576511
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, Geatti O, Castello A, Laghai I, Popescu CE, Dolci C, Crivellaro C, Seghezzi S, Kirienko M, De Biasi V, Cocciolillo F, Quartuccio N, Young AIMN Working Group.
    Eur J Nucl Med Mol Imaging; 2016 Mar 22; 43(3):404-13. PubMed ID: 26381775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.